LIXTE Biotechnology shares surge 19.08% after-hours after acquiring Liora's proton therapy LiGHT System.

Lixte Biotechnology Holdings (NASDAQ:LIXT) surged 19.08% in after-hours trading following the announcement of its acquisition of Liora Technologies, a pioneer in proton therapy systems for cancer treatment. The deal grants Lixte ownership of Liora’s proprietary LiGHT System, a linac-based proton therapy technology noted for its high-dose precision, reduced treatment sessions, and lower installation costs compared to existing systems. The acquisition aligns with Lixte’s focus on advancing cancer therapies and expanding its clinical-stage pipeline, with the LiGHT System’s potential to enhance treatment accessibility and efficacy. Endorsements from experts like Professor Steve Myers, former CERN accelerator director, further underscore the technology’s transformative potential, likely driving investor optimism about the company’s long-term growth and market differentiation.